SCH772984 improves survival in mouse models of sepsis and reduces plasma levels of Ccl2/Mcp1 chemokine. Kaplan–Meier survival curves of (A) LPS-treated C57BL/6W mice (20 mg/kg, i.p., n = 8 per group) or mice subjected to cecal ligation puncture (CLP) procedure (B) that were both injected i.p. with solvent control or 10 mg/kg of SCH772984 2 h after LPS administration/CLP procedure. (C) Plasma levels of indicated cytokines were measured with the 26-Plex Mouse ProcartaPlex immunoassay in CLP, SCH772984 (ERKi)-treated CLP, and sham-operated animals (n ≥ 6) at 6 and 12 h endpoint. ** p < 0.01, * p < 0.05 as determined by unpaired t-test. Only seven cytokines with significant alternations in plasma levels following SCH772984 are shown.